Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant CAPOX and Tislelizumab for Locally Advanced Rectal Cancer
NCT06647680Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in rectal cancer, sponsored by The Affiliated Hospital of Qingdao University. Started Jun 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06647680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647680.